Brind.

Report Finds Steep Access Barriers and High Costs for Medicare Drug Patients

1 report, 1 independent Updated Fri 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A report released by ICER and West Health, utilizing information from IQVIA, found that the median price for drugs launched in 2025 was $250,000. The analysis of over 200 novel drugs showed that only about one-third of outpatient prescriptions were filled within 30 days of being written. Medicare patients experienced the steepest access barriers and paid two to five times more out-of-pocket compared to those with commercial insurance.

From bioxconomy.com

Why it matters

Some supportBrind's analysis of the reports

The findings highlight significant disparities in drug affordability and access within the Medicare program. The report also noted that financial assistance programs designed to mitigate high list prices are facing criticism from payers. This points to systemic issues regarding drug pricing and patient costs.

From bioxconomy.com

Who's involved

  • IQVIAProvided longitudinal real-world information for the report.
  • ICERCollaborated with West Health to develop and publish the report.
  • West HealthPartnered with ICER to develop the report on healthcare affordability.
  • MedicareThe US federal health insurance program whose access barriers were analyzed.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • MedicareSpeculative

    Medicare might face increased regulatory pressure due to the highlighted access barriers and high out-of-pocket costs.

  • Eli Lilly and Company could face pressure on market pricing due to the report's findings on high drug costs.

  • HumanaSpeculative

    Humana could experience increased operational risk due to high out-of-pocket costs and access barriers for patients.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped